View the Table: Some Drugs for Inflammatory Bowel Disease

View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

The oral kinase inhibitors selpercatinib (Retevmo – Lilly) and pralsetinib (Gavreto – Blueprint Medicines/Genentech) have been approved by the FDA for treatment of advanced or metastatic RET-mutant or RET fusion-positive cancers. They are the first drugs to be approved specifically for certain RET-driven cancers. Both drugs were granted accelerated approval based on overall response rates and the duration of response.

The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and extended-release metformin, for oral treatment of type 2 diabetes in adults. Empagliflozin and linagliptin have been available in a fixed-dose combination as Glyxambi since 2015, and both have been available in 2-drug combinations with extended-release metformin for years (see Table 1).

View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025

View the Comparison Table: Some FDA-Approved Drugs for Weight Management

View Table 3: Some Drug Interactions with DAAs for HCV Infection

View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder

View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis